drugset
Drugs / maveropepimut-S
last change 3 days ago re-read 2 minutes ago

maveropepimut-S

also known as DPX-Survivac · MVP-S

Vaccine

Developed for
diffuse large B-cell lymphoma · fallopian tube cancer · ovarian cancer · peritoneum cancer · breast cancer · cancer of unknown primary site · ovarian epithelial tumor · primary peritoneal carcinoma
Investigated by
ImmunoVaccine Technologies, Inc. (IMV Inc.) · Merck Sharp & Dohme LLC · Providence Health & Services · Sunnybrook Health Sciences Centre · University Health Network, Toronto

Trials 7 · a red edge is where a trial was stopped

today NCT04895761 · Ph 1 NCT04920617 · Ph 2 NCT03349450 · Ph 2 NCT03029403 · Ph 2 NCT02323230 · Ph 2 NCT03332576 · Ph 1 NCT01416038 · Ph 1
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT04895761 Sep 2021 → Jun 2023 overdue breast cancer Providence Health & Services Active not recruiting No outcome recorded
Phase 1 NCT03332576 Aug 2013 → Sep 2016 fallopian tube cancer, ovarian epithelial tumor, peritoneum cancer ImmunoVaccine Technologies, Inc. (IMV Inc.) Completed No outcome recorded
Phase 1 NCT01416038 Dec 2011 → May 2013 fallopian tube cancer, ovarian cancer, peritoneum cancer ImmunoVaccine Technologies, Inc. (IMV Inc.) Completed No outcome recorded
Phase 24 trials
Phase 2 NCT04920617 Jun 2021 → Oct 2024 overdue diffuse large B-cell lymphoma ImmunoVaccine Technologies, Inc. (IMV Inc.) Recruiting No outcome recorded
Phase 2 NCT03349450 Mar 2018 → Oct 2021 diffuse large B-cell lymphoma Sunnybrook Health Sciences Centre Completed No outcome recorded
Phase 2 NCT03029403 Feb 2018 → Dec 2025 overdue cancer of unknown primary site, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma University Health Network, Toronto Active not recruiting No outcome recorded
Phase 2 NCT02323230 Jan 2015 → Jun 2017 diffuse large B-cell lymphoma ImmunoVaccine Technologies, Inc. (IMV Inc.) Terminated No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as maveropepimut-S “treated with maveropepimut-S (MVP-S, previously DPX-Survivac) a survivin directed T cell educating therapy, pembrolizumab, and intermittent low-dose cyclophosphamide.” PMID 37157906 ↗ May 2023
Known as DPX-Survivac “treated with maveropepimut-S (MVP-S, previously DPX-Survivac) a survivin directed T cell educating therapy, pembrolizumab, and intermittent low-dose cyclophosphamide.” PMID 37157906 ↗ May 2023
6

NCT04895761 ↗

NCT03029403 ↗

NCT03332576 ↗

NCT01416038 ↗

NCT02323230 ↗

NCT04920617 ↗
Known as MVP-S “treated with maveropepimut-S (MVP-S, previously DPX-Survivac) a survivin directed T cell educating therapy, pembrolizumab, and intermittent low-dose cyclophosphamide.” PMID 37157906 ↗ May 2023
Action Activate “acts to activate T cells” NCT04895761 ↗
Modality Vaccine “a novel cancer vaccine was formulated in DepoVax platform (DPX-Survivac)” PMID 26405584 ↗ May 2015
Route Subcutaneous “Vaccine targeting survivin antigen will be administered subcutaneously.” NCT01416038 ↗